Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?

@article{Rini2008TargetedTF,
  title={Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?},
  author={Brian I. Rini and Ronald M. Bukowski},
  journal={Oncology},
  year={2008},
  volume={22 4},
  pages={388-96; discussion 396, 402-3, 476 passim}
}
Recent advances in the understanding of the biology of renal cell carcinoma (RCC) have been translated into clinical treatment options in metastatic disease. The introduction of targeted therapy against the vascular endothelial growth factor (VEGF) pathway and related elements has produced robust clinical effects, exceeding those of historical treatment options. Sunitinib (Sutent) and bevacizumab (Avastin) plus interferon have established roles in the initial treatment of metastatic RCC… CONTINUE READING